Curated News
By: NewsRamp Editorial Staff
May 05, 2026

Oragenics Expands Phase IIa Concussion Trial to Second Site

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Oragenics advances Phase IIa trial for concussion treatment, positioning for early market entry and competitive advantage.
  • ONP-002 is delivered intranasally to target the brain, with Phase IIa enrollment underway at two sites for concussion.
  • Oragenics aims to improve patient outcomes for concussion and mild traumatic brain injury with a first-in-class therapy.
  • Oragenics uses intranasal delivery to bypass the blood-brain barrier, potentially treating Alzheimer's and PTSD too.

Impact - Why it Matters

This news matters because concussions and mild traumatic brain injuries are a major public health concern, affecting athletes, military personnel, and accident victims. Currently, there are no FDA-approved drugs specifically for concussion treatment, leaving patients with only rest and symptom management. Oragenics' ONP-002, if successful, could become the first targeted therapy, potentially reducing recovery time and preventing long-term cognitive damage. The use of intranasal delivery also opens doors for treating other neurological conditions, making this a pivotal moment in neurology.

Summary

Oragenics (NYSE American: OGEN) is making strides in the fight against concussions and mild traumatic brain injury (mTBI). The clinical-stage biotechnology company recently announced active enrollment at a second site for its Phase IIa clinical trial evaluating ONP-002, a potential first-in-class intranasal treatment. With four patients already dosed at the initial Australian site, Oragenics is progressing toward a planned data readout by year-end 2026. This milestone underscores the company's commitment to addressing a critical unmet medical need, as concussions affect millions annually with limited therapeutic options available.

ONP-002 leverages Oragenics' proprietary intranasal delivery technology, which bypasses the blood-brain barrier to deliver therapeutics directly to the brain. This platform has broad applications beyond concussion, including potential treatments for Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders. The company is working on commencing U.S. Phase 2b trials following the Australian study. This dual-site enrollment accelerates patient recruitment and brings us closer to understanding the drug's efficacy in a larger cohort.

The news was shared via BioMedWire, a specialized communications platform focusing on biotechnology and life sciences. BioMedWire is part of the Dynamic Brand Portfolio @ IBN, offering services like press release enhancement and social media distribution. For investors, the latest updates on Oragenics are available at https://ibn.fm/OGEN. With this progress, Oragenics is poised to potentially revolutionize concussion care, offering hope for faster recovery and reduced long-term cognitive decline.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Expands Phase IIa Concussion Trial to Second Site

blockchain registration record for this content.